STOCK TITAN

Seres Therapeutics Inc - MCRB STOCK NEWS

Welcome to our dedicated news page for Seres Therapeutics (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seres Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seres Therapeutics's position in the market.

Rhea-AI Summary
Seres Therapeutics, ticker symbol MCRB, will participate in the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023, at 3:30 p.m. ET. The audio webcast will be available on the company's website, with a replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
conferences
-
Rhea-AI Summary
Seres Therapeutics, Inc. reports Q3 2023 financial results, including VOWST net sales of $7.6 million. The company has received over 1,500 patient enrollment forms for VOWST since FDA approval. They also announced a strategic restructuring to focus on VOWST growth and reduce costs, resulting in a workforce reduction of 41% and anticipated annual cash savings of $75-$85 million in 2024. The restructuring is expected to support the company's operations into Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.28%
Tags
earnings
-
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB) will release its third quarter 2023 financial results on November 2, 2023. A conference call with investors will be held at 8:00 a.m. ET. The webcast replay will be available on the Seres website for approximately 21 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
earnings
Rhea-AI Summary
Seres Therapeutics announces multiple abstracts to be presented at IDWeek 2023, including post-hoc analyses from Phase 3 trials supporting the recent FDA approval of VOWST as the first orally-administered microbiota-based therapeutic for recurrent C. difficile infection in adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.72%
Tags
none
-
Rhea-AI Summary
Seres Therapeutics grants inducement equity grants to new employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.68%
Tags
none
-
Rhea-AI Summary
Seres Therapeutics grants inducement equity grants to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Rhea-AI Summary
Seres Therapeutics to participate at Morgan Stanley conference on September 11, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences
-
Rhea-AI Summary
Seres Therapeutics reports Q2 2023 financial results and updates on the commercial launch of VOWST, the first FDA-approved microbiome therapeutic for recurrent C. difficile infection. The early commercial uptake of VOWST is encouraging, with strong initial demand observed across healthcare providers and patient profiles. Phase 1b Cohort 1 data for SER-155 shows favorable tolerability and reduction in pathogen domination. The company expects coverage policies for VOWST to be issued in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.94%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences earnings
Seres Therapeutics Inc

Nasdaq:MCRB

MCRB Rankings

MCRB Stock Data

117.82M
118.74M
5.68%
59.48%
11.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About MCRB

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.